Background: The administration of the coronavirus disease 2019 (COVID-19) vaccine aims to stimulate the production of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. This leads to an enhanced production of neutralizing antibodies (Nabs), which naturally neutralize the virus within the body, thereby reducing the risk of COVID-19 infection. This study determined the analysis of factors affecting SARS-CoV-2 antibody levels in vaccinated individuals using data from the COVID-19 Seroepidemiological Survey of Gowa Regency.
View Article and Find Full Text PDF